The extensively drug resistant tuberculosis (XDR-TB) treatment market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses the market is growing at a CAGR of 8.10% in the above-mentioned research forecast period. Ongoing research on extensively drug resistant tuberculosis (XDR-TB) is the factor for the growth of extensively drug resistant tuberculosis (XDR-TB) treatment market.
For instance, Pretomanid is a novel compound which is developed by non-profit organization TB Alliance which had received FDA approval. This drug will be taken with the combination of bedaquiline and linezolid. This novel compound is used for the treatment of highly drug-resistant forms of tuberculosis such as extensively drug resistant tuberculosis.
Extensively drug resistant tuberculosis (XDR-TB) is characterized by the tuberculosis strain which is resistant to rifampicin and isoniazid. It is also resistant to the fluoroquinolone and from the one of the injection used for the treatment such as capreomycin, kanamycin and amikacin. XDR-TB was first discovered in 2006 and is considered as novel and incurable disease.
Download Exclusive Sample Report @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-extensively-drug-resistant-tuberculosis-xdr-tb-treatment-market
Market Analysis and Insights: Global Extensively Drug Resistant Tuberculosis (XDR-TB) Treatment Market:
Increase in patient population suffering from tuberculosis and extensively drug resistant tuberculosis (XDR-TB) may drive the extensively drug resistant tuberculosis (XDR-TB) treatment market growth. According to World Health Organization (WHO), there are 5,58,000 cases of drug resistant tuberculosis from which 8.5% cases are of XDR-TB and the treatment outcome for XDR-TB is 34%. There are 4,65,000 cases of rifampicin resistant tuberculosis in 2019. Increase in initiatives taken by the organizations such as World Health Organization (WHO) and institutes such as Centers for Disease Control and Prevention may also drive the extensively drug resistant tuberculosis (XDR-TB) treatment market growth. HIV patients associated with tuberculosis are at high risk of having extensively drug resistant tuberculosis (XDR-TB) which may drive the extensively drug resistant tuberculosis (XDR-TB) treatment market growth.
Unavailability of clinical approaches of XDR-TB and as the treatment is complicated and expensive with less cure and high mortality rate which may hamper the extensively drug resistant tuberculosis (XDR-TB) treatment market growth. For instance, the treatment cost of XRD-TB in the United States is USD 164,000.
Global Extensively Drug Resistant Tuberculosis (XDR-TB) Treatment Market Scope and Market Size
The extensively drug resistant tuberculosis (XDR-TB) treatment market is segmented on the basis of treatment type, route of administration, end-user and distribution channel. The growth among segments helps you analyse niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
· On the basis of treatment type, the extensively drug resistant tuberculosis (XDR-TB) treatment market is segmented into first line anti-TB drugs, second line anti-TB drugs and others. First line anti-TB drugs are further segmented to isoniazid, rifampicin, ethambutol, pyrazinamide, and others. Second line anti-TB drugs are further segmented to levofloxacin, moxifloxacin, bedaquiline, delamanid and linezolid.
· On the basis of route of administration, the extensively drug resistant tuberculosis (XDR-TB) treatment market is segmented into oral, parenteral and others.
· On the basis of end-user, the extensively drug resistant tuberculosis (XDR-TB) treatment market is segmented to hospitals, homecare, specialty clinics and others.
Table of Contents: Global Extensively Drug Resistant Tuberculosis (XDR-TB) Treatment Market
1 Introduction
2 Market Segmentation
3 Executive Summary
4 Premium Insight
5 Market Overview
6 Covid-19 Impact on Extensively Drug Resistant Tuberculosis (XDR-TB) Treatment in Healthcare Industry
7 Global Extensively Drug Resistant Tuberculosis (XDR-TB) Treatment Market, by Product Type
8 Global Extensively Drug Resistant Tuberculosis (XDR-TB) Treatment Market, by Modality
9 Global Extensively Drug Resistant Tuberculosis (XDR-TB) Treatment Market, by Type
10 Global Extensively Drug Resistant Tuberculosis (XDR-TB) Treatment Market, by Mode
11 Global Extensively Drug Resistant Tuberculosis (XDR-TB) Treatment Market, by End User
12 Global Extensively Drug Resistant Tuberculosis (XDR-TB) Treatment Market, by Geography
13 Global Extensively Drug Resistant Tuberculosis (XDR-TB) Treatment Market, Company Landscape
14 Swot Analysis
15 Company Profiles
16 Questionnaire
17 Related Reports
Browse Full Report Along with Facts and Figures @ https://www.databridgemarketresearch.com/reports/global-extensively-drug-resistant-tuberculosis-xdr-tb-treatment-market
Some Trending Reports of Healthcare Industry:
About Us:
Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge Market Research provides appropriate solutions to the complex business challenges and initiates an effortless decision-making process.
Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude. Get Customization and Discount on Report by emailing sopan.gedam@databridgemarketresearch.com . We are content with our glorious 99.9 % client satisfying rate.
Contact Us:
US: +1 888 387 2818
UK: +44 208 089 1725
Hong Kong: +852 8192 7475
Email – corporatesales@databridgemarketresearch.com
